AI Insight
Researchers have developed an experimental drug called CS18 that targets multiple defense mechanisms cancer cells use to resist treatment. In laboratory studies, CS18 enhanced the effectiveness of existing cancer therapies and restored sensitivity to drugs in resistant lung cancer cells. The compound also demonstrated the ability to slow tumor growth when tested in animal models.
Why it matters
Drug resistance is a major obstacle in cancer treatment, often limiting the long-term effectiveness of therapies and contributing to treatment failure. If CS18 proves successful in human trials, it could provide a new strategy to overcome resistance and improve outcomes for patients whose cancers no longer respond to standard treatments.
Understand the Science
A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models.
Source: This new drug could break cancer’s resistance to treatment